Formulary guidance and transparency from P&T to point of care

Trends That Matter for Immune Globulin

Posted by Matt Breese on Mar 1, 2018

Find me on:


In our weekly Trends That Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is Immune Globulin. 

According to our recent payer coverage analysis for immune globulin, combined with news from key health care influencers, market access is shifting in this drug landscape. Pharmacy benefit coverage shows a tremendous increase in restrictive Medicare formularies and a similar shift for health exchange formularies, while standard commercial plans are relaxing coverage.

Here are some recent trends:

  • Steady M&A Activity as 2018 Theme: While 2017 merger and acquisition (M&A) activity within the specialty pharmacy and infusion therapy arenas may not have met the numbers of past years, both industries were stable. Reg Blackburn, managing director at The Braff Group, notes a steady state of M&A activity in specialty pharmacy is expected in 2018, with “independent pharmacies wanting to exit, but buyers being picky.” The trend of some HIV drugs going generic is also a positive driver for the specialty space. 
  • Medicare IVIG Demo Extension: Introduced by Rep. Kevin Brady (R-Texas) July 10, the bill was aimed at extending the three-year Medicare Patient IVIG Access Demonstration Project. Through the demo, Medicare provides a per-visit payment for items and services needed to administer intravenous immune globulin at home. 

To learn more about this topic, download MMIT's Reality Check by clicking on the button below: 

View Reality Check 

Topics: Specialty, Industry Trends